1. Dutkiewicz S. Badania nad określeniem czynników warunkujących wybór leczenia farmakologicznego lub chirurgicznego u chorych na łagodny rozrost stercza. Legraf, Warszawa 1996

2. Dutkiewicz S, red. Choroby stercza (gruczołu krokowego). Wyd. Med. Termedia, Poznań 2010.

3. Roehborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 2011;95:87-100.

4. Cruz F, Desgrandchamps F. New concepts and pathophysiology of lower urinary tract symptoms in men. Eur Urol 2010;suppl 9:472-476.

5. Oelke M, Baard J, Wijkstra H, et al. Age and bladder obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008;54:419-426.

6. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Am J Obstet Gynec 2002; 187:116-126.

7. Dutkiewicz S. Współczesna farmakoterapia chorych na łagodny rozrost stercza (BPH/LUTS). Lek w Polsce 2013; vol.23,nr 1 (261): 11- 16.

8. Thomas AW, Cannon A, Bartlett E, et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of transurethral resection of prostate for bladder outlet obstruction. J Urol 2005; 174:1887-1891.

9. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 2011; 95:87-100.

10. Sarma AV, Jacobson DJ, McGree ME, et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmstead County, Minnesota: 1987 to 1997. J Urol 2005:173:2048-2053.

11. Chapple Ch. Overview of evidence for contemporary management of lower urinary tract symptoms presumed due to benign prostatic hyperplasia in males. Eue Urol 2010; suppl 9: 482-485.

12. Charakterystyka produktu leczniczego Urorec (4 mg, 8 mg) 2010.

13. Montorsi F. Profile of Silodosin. Eur Urol suppl. 2010; 9(4): 491-495.

14. Yoshida M, Kudoh J, Homma Y, Kawabo K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clinical Interventions in Aging 2011; 6: 161-172.

15. Roehrborn CG. The utility of serum PSA in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20(suppl 3): 19-26.

16. Dorsam J, AltweinJ. 5 alpha-reductase inhibitor treatment of prostatic diseases: bachground and practical implications. Prostate Cancer Prostatic Disease 2009; 12:130-136.

17. Fenter TC, Davis EA, Shah NB, et al. Dutasteride vs Finasteryde: Assessement of differences in acute urinary retention rates and surgical risk outcomes in an erderly population aged >65 years. Am J Manag Care 2008; 14: 154-159.

18. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 328-332.

19. Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-relaese in men with overactive bladder and urgency incontinence. BJU Int 2006; 97: 1003-1006.

20. Abrams P, Kaplan S, DeKonig HJ, et al. Safety and torelability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999-1004.

21. Masumori N, Tsukamoto T, Yanase M, et al. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol 2010; 250-251.

22. Dutkiewicz S. Mirabegron w leczeniu nietrzymania moczu (NM) i pęcherza nadreaktywnego (OAB) oraz innych objawów dolnego odcinka dróg moczowych (LUTS). Lek w Polsce 2014; 24,7/8(279): 44-48.

23. Kuzaka B, Niemirko M, Kuzaka P, Czaplicki M. Leki ziołowe w leczeniu łagodnego rozrostu gruczołu krokowego. Przegl Urol 2012; 2(72) supl.1-18.